<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872625</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633331</org_study_id>
    <secondary_id>CALACASS-CYBERNEO</secondary_id>
    <secondary_id>CALACASS-2006/24</secondary_id>
    <secondary_id>INCA-RECF0621</secondary_id>
    <secondary_id>EUDRACT-2006-A00250-51</secondary_id>
    <nct_id>NCT00872625</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer</brief_title>
  <official_title>Phase I Study - Hypofractionated Cyberknife Radiotherapy Combined With Neoadjuvant Chemotherapy for Breast Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation
      therapy in higher doses over a shorter period of time may kill more tumor cells and have
      fewer side effects. Drugs used in chemotherapy, such as docetaxel, epirubicin,
      cyclophosphamide, and fluorouracil, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving more than one drug
      (combination chemotherapy) together with radiation therapy may kill more tumor cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of radiation therapy
      when given together with docetaxel followed by standard therapy in treating women with breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the tolerance to concurrent neoadjuvant docetaxel and cyberknife
           hypofractionated radiotherapy followed by standard treatment in women with breast cancer
           in order to find the maximum-tolerated dose of radiotherapy.

      Secondary

        -  Evaluate the efficacy of the combination chemoradiotherapy.

        -  Evaluate breast-conserving surgery.

        -  Evaluate the quality of life.

      OUTLINE: This is a dose-escalation study of cyberknife hypofractionated radiotherapy.

      Patients receive neoadjuvant docetaxel IV on day 1. Treatment repeats every 3 weeks for up to
      3 courses in the absence of disease progression or unacceptable toxicity. Beginning during
      the first or second course of neoadjuvant chemotherapy, patients undergo hypofractionated
      radiotherapy. Patients then receive standard chemotherapy comprising epirubicin hydrochloride
      IV, cyclophosphamide IV, and fluorouracil IV on day 1. Treatment repeats every 3 weeks for up
      to 3 courses in the absence of disease progression or unacceptable toxicity. Patients undergo
      surgery 4-8 weeks after the last course of chemotherapy, and then undergo standard
      radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose of radiotherapy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cyberknife</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiation therapy</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>image-guided radiation therapy</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of breast cancer

               -  Unifocal disease

               -  Non-metastatic disease

               -  Not a candidate for breast-conserving surgery

          -  No superficial breast cancer (defined as the distance between tumor and skin â‰¤ 1 cm)

          -  Undergone MRI of the breast to define the macroscopic tumor volume

          -  Undergone scanning of the breast to mark the location for radiotherapy

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  No counter-indications to surgery, standard neoadjuvant chemotherapy, or insertion of
             an implantable venous device

          -  No patient for whom clinical follow up is impossible for psychological, familial,
             social, or geographical reasons

          -  No patients deprived of liberty or under trusteeship

        PRIOR CONCURRENT THERAPY:

          -  No prior ipsilateral breast irradiation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Yves Bondiau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2009</study_first_submitted>
  <study_first_submitted_qc>March 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <last_update_submitted>February 8, 2015</last_update_submitted>
  <last_update_submitted_qc>February 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

